These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20490358)

  • 21. Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats.
    Janiak P; Bidouard JP; Cadrouvele C; Poirier B; Gouraud L; Grataloup Y; Pierre F; Bruneval P; O'Connor SE; Herbert JM
    Eur J Pharmacol; 2006 Mar; 534(1-3):271-9. PubMed ID: 16516882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4-5 chronic kidney disease.
    Tamura Y; Kosuga M; Yamashita M; Tomioka S; Sasaki M; Hikita T; Nakajima H; Kojima K; Uchida S
    Clin Exp Nephrol; 2008 Aug; 12(4):256-263. PubMed ID: 18317875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renoprotective effects of angiotensin receptor blocker and stem cells in acute kidney injury: Involvement of inflammatory and apoptotic markers.
    Sherif IO; Al-Mutabagani LA; Alnakhli AM; Sobh MA; Mohammed HE
    Exp Biol Med (Maywood); 2015 Dec; 240(12):1572-9. PubMed ID: 25825359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxidative stress contributes to orthopedic trauma-induced acute kidney injury in obese rats.
    Mittwede PN; Xiang L; Lu S; Clemmer JS; Hester RL
    Am J Physiol Renal Physiol; 2015 Jan; 308(2):F157-63. PubMed ID: 25428128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different effects of angiotensin receptor blockade on end-organ damage in salt-dependent and salt-independent hypertension.
    Maitland K; Bridges L; Davis WP; Loscalzo J; Pointer MA
    Circulation; 2006 Aug; 114(9):905-11. PubMed ID: 16923758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
    Calkin AC; Giunti S; Sheehy KJ; Chew C; Boolell V; Rajaram YS; Cooper ME; Jandeleit-Dahm KA
    Diabetologia; 2008 Sep; 51(9):1731-40. PubMed ID: 18594792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Involvement of angiotensin II type 1 receptor on pathological remodeling and dysfunction in obstructed bladder.
    Aikawa K; Sakai T; Ishibashi K; Shiomi H; Sagawa K; Kumagai S; Kataoka M; Akaihata H; Yamaguchi O
    Int J Urol; 2012 May; 19(5):457-64. PubMed ID: 22320898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure.
    White M; Lepage S; Lavoie J; De Denus S; Leblanc MH; Gossard D; Whittom L; Racine N; Ducharme A; Dabouz F; Rouleau JL; Touyz R
    J Card Fail; 2007 Mar; 13(2):86-94. PubMed ID: 17395047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.
    Willemsen JM; Rabelink TJ; Boer P; Gaillard CA
    J Hum Hypertens; 2004 Dec; 18(12):857-63. PubMed ID: 15361886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Olmesartan ameliorates renovascular injury and oxidative stress in Zucker obese rats enhanced by dietary protein.
    Namikoshi T; Tomita N; Satoh M; Haruna Y; Kobayashi S; Komai N; Sasaki T; Kashihara N
    Am J Hypertens; 2007 Oct; 20(10):1085-91. PubMed ID: 17903692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies.
    Liu H; Kitazato KT; Uno M; Yagi K; Kanematsu Y; Tamura T; Tada Y; Kinouchi T; Nagahiro S
    J Hypertens; 2008 Jul; 26(7):1435-45. PubMed ID: 18551021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease.
    Frimodt-Møller M; Høj Nielsen A; Strandgaard S; Kamper AL
    Nephrol Dial Transplant; 2010 Mar; 25(3):842-7. PubMed ID: 19903661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin blockade in diabetic patients decreases insulin resistance-associated low-grade inflammation.
    Pavlatou MG; Mastorakos G; Margeli A; Kouskouni E; Tentolouris N; Katsilambros N; Chrousos GP; Papassotiriou I
    Eur J Clin Invest; 2011 Jun; 41(6):652-8. PubMed ID: 21175613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats.
    Nagai M; Horikoshi K; Izumi T; Seki S; Taniguchi M; Taniguchi I; Mochizuki S
    Cardiovasc Drugs Ther; 2004 Sep; 18(5):353-62. PubMed ID: 15717137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria.
    Kincaid-Smith P; Fairley K; Packham D
    Nephrol Dial Transplant; 2002 Apr; 17(4):597-601. PubMed ID: 11917051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of angiotensin II type 1 receptor blocker on islet of diabetic db/db mice].
    Shao JQ; Iwashita N; Du H; Wang YY; Zhao M; Wang J; Watada H; Kawamori R
    Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):306-10. PubMed ID: 17637271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Candesartan, rather than losartan, improves motor dysfunction in thioacetamide-induced chronic liver failure in rats.
    Murad HA; Gazzaz ZJ; Ali SS; Ibraheem MS
    Braz J Med Biol Res; 2017 Sep; 50(11):e6665. PubMed ID: 28953991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Candesartan prevents long-term impairment of renal function in response to neonatal partial unilateral ureteral obstruction.
    Topcu SO; Pedersen M; Nørregaard R; Wang G; Knepper M; Djurhuus JC; Nielsen S; Jørgensen TM; Frøkiaer J
    Am J Physiol Renal Physiol; 2007 Feb; 292(2):F736-48. PubMed ID: 17032940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.
    Saruta T; Hayashi K; Ogihara T; Nakao K; Fukui T; Fukiyama K;
    Hypertens Res; 2009 Jun; 32(6):505-12. PubMed ID: 19390535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.